MUMBAI, India and MAHWAH, N.J., June 28, 2022 /PRNewswire/ — Glenmark Prescribed drugs Ltd., an innovation-pushed, global pharmaceutical enterprise, announced that its completely owned subsidiary Glenmark Pharmaceuticals Inc., United states of america (Glenmark) has acquired the accredited Abbreviated New Drug Apps (ANDAs) for Famotidine Tablets USP, 10 mg and 20 mg (OTC), Cetirizine Hydrochloride Tablets USP, 5 mg and 10 mg (OTC), Lansoprazole Delayed-Release Capsules USP, 15 mg (OTC) and Olopatadine Hydrochloride Ophthalmic Remedy USP, .1% (OTC) in the United States from Wockhardt Constrained.
Sanjeev Krishan, President of Glenmark Pharmaceuticals Inc., United states, commented, “The in excess of-the-counter industry has prolonged been an crucial phase of Glenmark’s portfolio close to the environment. Our acquisition of these ANDAs represents the continued growth of our small business into the OTC marketplace below in the United States and our dedication to making certain sufferers have obtain to higher good quality, inexpensive medicines.”
Glenmark’s latest portfolio consists of 175 merchandise authorized for distribution in the U.S. marketplace and 48 ANDAs pending approval with the U.S. Food and drug administration. In addition to these inside filings, Glenmark continues to determine and discover exterior progress partnerships to health supplement and speed up the progress of its current pipeline and portfolio.
About Glenmark Pharmaceuticals Ltd.
Glenmark Prescribed drugs Ltd. (BSE: 532296) (NSE: GLENMARK) is an innovation-driven world-wide pharmaceutical corporation with a presence across Specialty, Generics and OTC companies. It focuses on the crucial therapeutic regions of respiratory, dermatology and oncology. The company has 10 world-course manufacturing amenities spread across 4 continents and functions in more than 80 international locations. Glenmark is rated between the world’s best 100 biopharmaceutical companies (Best 100 Businesses Rated by Pharmaceutical Profits, 2020, by In Vivo/Scrip 100) and amongst the world’s top 50 businesses in the off-patent sector (Prime 50 Generics and Biosimilars Firms ranked by Revenue, 2020, by Generics Bulletin/In Vivo). The business was mentioned on the Dow Jones Sustainability Index (DJSI), one particular of the world’s most highly regarded and extensively approved sustainability benchmarks, below the class of rising markets (2021) for the fourth consecutive yr in a row. For more information, pay a visit to www.glenmarkpharma.com.
Abide by us on Social Media:
Watch first content material:https://www.prnewswire.com/news-releases/glenmark-prescribed drugs-inc-usa-continues-to-expand-its-above-the-counter-otc-portfolio-with-the-acquisition-of-approved-andas-from-wockhardt-restricted-301576873.html
Resource Glenmark Prescribed drugs Ltd.